ArriVent BioPharma (AVBP)
Develops licensed oncology assets led by firmonertinib and antibody-drug conjugates.
$30.32
After hours−0.03 (−0.10%)
At close$30.35(+2.05%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 93.61% | 46.16M shares | |
|---|---|---|---|
| 166 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.08% | 530.2K shares | |
| 1 holder · as of Jul 15, 2025 | |||
| Strategic holders | 12.42% | 6.12M shares | |
| 2 holders · as of Feb 17, 2026 | |||
| Adds to | 107.11% | ||
49.31M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 107.11%; nothing is left for Other.
13F, as of Jun 30, 2026
166 holders · 46.16M shares · 39 new positions · 112 increased · 30 reduced · 16 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 4.52M | 9.16% | +114.4K | Aug 14, 2026 |
| Infinitum Asset Management, LLC | 4.44M | 9.00% | +289.5K | Aug 14, 2026 |
| HHLR Advisors, Ltd. | 3.93M | 7.97% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 3.25M | 6.59% | +720.1K | Aug 7, 2026 |
| Orbimed Advisors LLC | 3.03M | 6.14% | 0 | Aug 14, 2026 |
| FMR LLC | 2.78M | 5.64% | −237.2K | Aug 13, 2026 |
| Octagon Capital Advisors LP | 1.97M | 4.00% | 0 | Aug 14, 2026 |
| Vanguard Capital Management LLC | 1.77M | 3.60% | +246.0K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Infinitum Asset Management, LLC | 9.90% | 4.12M | 13G | Feb 17, 2026 |
| Suvretta Capital Management, LLC | 9.90% | 3.41M | 13G | Aug 13, 2025 |
| Hillhouse Investment Management, Ltd. | 9.50% | 3.93M | 13G | Feb 17, 2026 |
| Orbimed Advisors LLCincl. OrbiMed Asia GP IV, L.P., OrbiMed Capital GP VIII LLC +1 more | 7.50% | 3.03M | 13D | Aug 13, 2025 |
| FMR LLC | 6.80% | 3.02M | 13G | May 6, 2026 |
| Aaron Cowenincl. Averill Master Fund, Ltd., Suvretta Capital Management, LLC | 6.10% | 2.04M | 13G | Dec 4, 2024 |
| Ting Jiaincl. Octagon Capital Advisors LP, Octagon Investments Master Fund LP +2 more | 5.90% | 1.98M | 13G | Oct 11, 2024 |
| BlackRock, Inc. | 5.60% | 2.32M | 13G | Jan 21, 2026 |
| HBM Healthcare Investments (Cayman) Ltd. | 5.40% | 2.20M | 13G | Oct 15, 2025 |
| Sofinnova Management XI, L.P. (“SM XI LP”)incl. Sofinnova Management XI, L.L.C. (“SM XI LLC”), Dr. James I. Healy (“Healy”) +2 more | 5.10% | 1.70M | 13G | Nov 12, 2024 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Dec 10, 2025 | Hillhouse Investment Management, Ltd.10 percent owner | Sale | 555,555 | $23.37 | 3,929,117 |
House and Senate disclosures
Not reported.